155 related articles for article (PubMed ID: 38552777)
1. 2023 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2024 May; 29(5):103966. PubMed ID: 38552777
[TBL] [Abstract][Full Text] [Related]
2. 2022 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2023 Aug; 28(8):103622. PubMed ID: 37201782
[TBL] [Abstract][Full Text] [Related]
3. 2016 in review: FDA approvals of new molecular entities.
Griesenauer RH; Kinch MS
Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
[TBL] [Abstract][Full Text] [Related]
4. 2021 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2022 Aug; 27(8):2057-2064. PubMed ID: 35439613
[TBL] [Abstract][Full Text] [Related]
5. 2018 in review: FDA approvals of new molecular entities.
Kinch MS; Griesenauer RH
Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
[TBL] [Abstract][Full Text] [Related]
6. 2020 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2021 Dec; 26(12):2794-2799. PubMed ID: 34252611
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmic Drug Discovery in the United States over the past Two Decades.
Gu D; Janetos TM
Ophthalmic Epidemiol; 2021 Feb; 28(1):21-26. PubMed ID: 32597285
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
9. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
10. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
Torre BG; Albericio F
Molecules; 2021 Jan; 26(3):. PubMed ID: 33504104
[TBL] [Abstract][Full Text] [Related]
11. The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164339
[TBL] [Abstract][Full Text] [Related]
12. Investigating the landscape of US orphan product approvals.
Miller KL; Lanthier M
Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
[TBL] [Abstract][Full Text] [Related]
13. 2017 in review: FDA approvals of new molecular entities.
Kinch MS; Griesenauer RH
Drug Discov Today; 2018 Aug; 23(8):1469-1473. PubMed ID: 29751111
[TBL] [Abstract][Full Text] [Related]
14. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
15. 2015 in review: FDA approval of new drugs.
Kinch MS
Drug Discov Today; 2016 Jul; 21(7):1046-50. PubMed ID: 27109618
[TBL] [Abstract][Full Text] [Related]
16. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
17. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
Kaitin KI; Manocchia M
Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
[TBL] [Abstract][Full Text] [Related]
18. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
19. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
20. Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022.
Seoane-Vazquez E; Rodriguez-Monguio R; Powers JH
Sci Rep; 2024 Feb; 14(1):3325. PubMed ID: 38336899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
